Systemic treatment of HCC in special populations
-
Published:2021-04
Issue:4
Volume:74
Page:931-943
-
ISSN:0168-8278
-
Container-title:Journal of Hepatology
-
language:en
-
Short-container-title:Journal of Hepatology
Author:
Rimassa LorenzaORCID,
Personeni NicolaORCID,
Czauderna Carolin,
Foerster FriedrichORCID,
Galle PeterORCID
Reference136 articles.
1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
2. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
4. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N Engl J Med,2018
5. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Zhu;Lancet Oncol,2019
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献